Aberrant RET signaling drives multiple malignancies including non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma, pancreatic cancer, and prostate cancer (Ahn et al., 2020; Cascetta et al., 2021). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.